Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash from Investing Activities (2017 - 2026)

Cogent Biosciences' Cash from Investing Activities history spans 9 years, with the latest figure at -$36.5 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 152.55% to -$36.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$505.4 million through Mar 2026, down 574.02% year-over-year, with the annual reading at -$399.5 million for FY2025, 1143.8% down from the prior year.
  • Cash from Investing Activities came in at -$36.5 million for Q1 2026, up from -$322.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $69.4 million in Q1 2025 to a low of -$322.8 million in Q4 2025.
  • The 5-year median for Cash from Investing Activities is -$441000.0 (2022), against an average of -$36.5 million.
  • Year-over-year, Cash from Investing Activities crashed 12930.44% in 2022 and then skyrocketed 13679.14% in 2023.
  • Cogent Biosciences' Cash from Investing Activities stood at $28.4 million in 2022, then crashed by 63.08% to $10.5 million in 2023, then surged by 487.96% to $61.7 million in 2024, then plummeted by 623.37% to -$322.8 million in 2025, then skyrocketed by 88.7% to -$36.5 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Cash from Investing Activities are -$36.5 million (Q1 2026), -$322.8 million (Q4 2025), and -$155.0 million (Q3 2025).